



CIGNA MEDICAL COVERAGE POLICY

The following Coverage Policy applies to all plans administered by CIGNA Companies including plans administered by Great-West Healthcare, which is now a part of CIGNA.

Subject Computed Tomography Angiography (CTA)

Effective Date 9/15/2009
Next Review Date 8/15/2010
Coverage Policy Number 0399

Table of Contents

Coverage Policy	1
General Background	2
Coding/Billing Information	12
References	14
Policy History	21

Hyperlink to Related Coverage Policies

Cardiovascular Magnetic Resonance (CMR)
Electron Beam Computed Tomography (EBCT) and Multidetector Computed Tomography (MDCT) for Coronary Artery Calcification
Magnetic Resonance Angiography (MRA)

INSTRUCTIONS FOR USE

Coverage Policies are intended to provide guidance in interpreting certain **standard** CIGNA HealthCare benefit plans as well as benefit plans formerly administered by Great-West Healthcare. Please note, the terms of a participant's particular benefit plan document [Group Service Agreement (GSA), Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a participant's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a participant's benefit plan document **always supercedes** the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable group benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. Proprietary information of CIGNA. Copyright ©2009 CIGNA

Coverage Policy

CIGNA covers multidetector-row computed tomography angiography (CTA) as medically necessary as an adjunct to other testing for ANY of the following indications:

- diagnostic head and neck vascular imaging for suspected pathology (e.g., suspected or known stroke, subarachnoid hemorrhage, aneurysm, atherosclerotic disease, arteriovenous malformation)
- screening for intracranial aneurysm for EITHER of the following:
 - an individual with a heritable disorder known to be associated with vascular anomalies (e.g., autosomal dominant polycystic kidney disease, Ehlers-Danlos syndrome, fibromuscular dysplasia, or a known aortic coarctation)
 - an individual with at least one first-degree relative with a history of intracranial aneurysm
- surveillance of intracranial aneurysm in an individual with EITHER of the following:
 - a known unruptured intracranial aneurysm
 - an intracranial aneurysm previously treated with endovascular coiling or neurosurgical clipping
- diagnostic thoracic vascular imaging for suspected pathology (e.g., suspected or known aortic dissection or aneurysm, arteriovenous malformation, pulmonary artery hypertension, thoracic outlet syndrome)
- suspected or known pulmonary embolism
- diagnostic abdominal vascular imaging for suspected pathology (e.g., suspected or known abdominal aortic aneurysm or dissection, renovascular hypertension)
- evaluation of suspected or known peripheral arterial disease

- evaluation of suspected or known vascular anomalies associated with congenital conditions (e.g., Marfan syndrome, pulmonary sequestration, complete and incomplete vascular rings)
- evaluation of the pulmonary veins and left atrium prior to radiofrequency ablation for atrial fibrillation or supraventricular tachycardia

CIGNA covers 64-slice or greater multidetector-row computed tomography angiography (CTA) as medically necessary as an adjunct to other testing for ANY of the following indications:

- evaluation of chest pain in an individual with a very low, low, or intermediate pre-test probability of coronary artery disease¹ (CAD) when the individual cannot perform or has a contraindication to exercise and chemical stress testing (i.e. exercise treadmill stress test, stress echo, and nuclear stress test [i.e., myocardial perfusion imaging])
- exclusion of CAD in an individual with a low or very low pre-test probability of CAD when recent stress test results (i.e., exercise treadmill, stress echo, or nuclear stress test [i.e., myocardial perfusion imaging]) are uninterpretable, equivocal, or there is a suspicion that the results are falsely positive
- exclusion of CAD in an individual with an intermediate pre-test probability of CAD when recent stress test results (i.e., exercise treadmill, stress echo, or nuclear stress test [i.e., myocardial perfusion imaging]) are uninterpretable or equivocal, AND CTA will be performed in lieu of an angiography.
- exclusion of CAD in a symptomatic individual (e.g., acute chest pain in an emergency department setting), and the individual has an intermediate pre-angiography probability of CAD, and there are no changes noted on the ECG and serial enzymes are negative
- evaluation of suspected or known coronary artery anomalies associated with congenital conditions
- for morphologic evaluation of the coronary arteries in an individual with dilated cardiomyopathy or new onset heart failure, when ischemia is the suspected etiology and cardiac catheterization and/or nuclear stress test (i.e., myocardial perfusion imaging) have not been performed
- pre-operative assessment of coronary arteries in an individual undergoing repair of aortic dissection, aortic aneurysm repair or valvular surgery AND CTA will be performed in lieu of an angiography
- post-coronary artery bypass grafting (CABG) when BOTH of the following criteria are met:
 - repeat intervention is being considered
 - recent coronary angiography has been completed but additional information is needed before a treatment decision can be made

CIGNA does not cover multidetector-row computed tomography angiography (CTA) for any other indication, including but not limited to those listed below, because it is considered experimental, investigational or unproven:

- evaluation of chest pain in an intermediate or high pre-test probability of CAD individual when recent stress test result (i.e., exercise treadmill, stress echo, or nuclear stress test [i.e., myocardial perfusion imaging]) are either clearly positive or unequivocally negative
- screening for CAD in an asymptomatic individual
- post-revascularization procedure (e.g., percutaneous coronary intervention, coronary artery bypass grafting surgery), including evaluation of bypass grafts, coronary anatomy or evaluation for in-stent restenosis except when an individual is post-coronary artery bypass grafting (CABG), repeat intervention is being considered but additional information is required following completion of recent coronary angiography.

¹ See Appendix A for definition of Pre-test Probability of CAD

General Background

The American College of Radiology (ACR) defines computed tomography angiography (CTA) as “a CT examination that is primarily performed for assessment of the heart, arteries, or veins of the body. It requires at a minimum a thin section helical (spiral) CT acquisition coupled with a power injection of intravenous iodinated contrast medium. Three dimensional rendering and multiplanar reformations are important components of many CTA examinations” (ACR, 2006). Computed tomography angiography or venography (CTA/CTV) involves injecting contrast material into a small peripheral vein by using a small needle or catheter to visualize blood flow

in arterial and venous vessels throughout the body. Images are generated by a computer synthesis of x-ray transmission data obtained in many different directions in a given plane. Compared to catheter angiography, which involves placing a sizable catheter and injecting contrast material into a large artery or vein, CTA/CTV is a noninvasive procedure.

Imaging of the vessels is not necessarily CTA. The key distinction between CTA and CT is that “CTA includes reconstruction post-processing of angiographic images and interpretation. It is not a CTA study unless reconstruction post-processing is performed. CTA utilizes images that are obtained with a large volume of rapidly injected intravenous contrast, acquired with narrow collimation and reconstructed at narrower intervals than standard CT images. The scans are optimized specifically for visualization of the arterial and venous anatomy and any associated vascular anomalies. The acquired data set is then evaluated with the aid of computer reconstruction. CTA offers important advantages over conventional angiography, which depicts only the vascular lumen. With CTA, additional information is provided, including vessel wall thickness, relationship to adjacent structures, enhanced depiction of the venous anatomy, and parenchymal information of the target organ and other structures within the scan range and field of view” (ACR, July 2001).

U.S. Food and Drug Administration (FDA)

Multiple manufacturers have received FDA 510(k) clearance to market CT machines. Multislice CT technology has evolved rapidly over the past several years, beginning with 4-slice scanners that were first introduced in 1998. Since then, multi-slice scanners have been approved and available for diagnostic use, with the first 64-slice system receiving FDA approval in 2004.

Literature Review

Head and Neck

CTA/CTV is a useful modality when head and neck vascular visualization is needed. CTA may be performed for suspected or known stroke, subarachnoid hemorrhage, aneurysm, atherosclerotic disease, and arteriovenous malformation. CTA can also be used to examine the intracranial venous system (CT venography, CTV), such as suspected dural sinus thrombosis. Due to its high sensitivity, the majority of studies support the use of CTA as a substitute for catheter angiography. Studies demonstrate that CTA has a significant positive effect on patient clinical management, or possibly avoids a potentially harmful procedure, digital subtraction angiography, or provides important preoperative information (Bash, et al., 2005; Koelemay, et al., 2004; Schramm, et al., 2004; Chappell, et al., 2003; Kokkinis, et al., 2008; Chen, et al., 2008).

American Heart Association and American Stroke Association (AHA/ASA): The AHA/ASA published recommendations regarding evaluation of transient ischemic attack (Easton, et al., 2009). There was one recommendation specific to CTA: Initial assessment of the extracranial vasculature may involve any of the following: carotid ultrasound/transcranial Doppler, MR angiography, or CT angiography, depending on local availability and expertise, and characteristics of the patient (Class IIa).

See Appendix B for American College of Cardiology/American Heart Association (ACC/AHA) Definitions of Classification.

European Federation of Neurological Societies (EFNS): The EFNS Guideline on Neuroimaging in Acute Stroke (Masdeu, et al., 2006) states the following regarding CTA:

- Imaging of Extracranial Vessels: CTA has a sensitivity and specificity similar to MR for carotid occlusion and similar to US for the detection of severe stenosis (Class II).
- Imaging of Intracranial Vessels: MRA and CTA are very useful for the diagnosis of intracranial stenosis and cerebral aneurysms > 5 mm (Class II).

Evidence classification scheme for a diagnostic procedure:

Class I: A prospective study in a broad spectrum of persons with the suspected condition, using a gold standard for case definition, where the test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy

Class II: A prospective study of a narrow spectrum of persons with the suspected condition, or a well-designed retrospective study of a broad spectrum of persons with an established condition (by gold standard) compared with a broad spectrum of controls, where test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy

Class III: Evidence provided by a retrospective study where either persons with the established condition or controls are of a narrow spectrum, and where test is applied in a blinded evaluation

Class IV: Any design where test is not applied in blinded evaluation OR evidence provided by expert opinion alone or in descriptive case series (without controls)

Screening for and Surveillance of Intracranial Aneurysms

Evidence in the peer-reviewed scientific literature supports screening for and surveillance of intracranial aneurysms with CTA or MRA for certain population subsets. Specifically, the literature supports screening for individuals with a rare heritable disorder known to be associated with vascular anomalies (e.g., autosomal dominant polycystic kidney disease, Ehlers-Danlos syndrome, fibromuscular dysplasia, a known aortic coarctation). Additionally the literature supports screening in individuals with at least one first-degree relative with a history of intracranial aneurysm. Study results vary, but generally, screening becomes even more critical if the individual has greater than one first-degree relative with a history of intracranial aneurysm (i.e., familial intracranial aneurysm) and if that individual also has a personal history of hypertension, smoking, or takes oral contraceptives. Because the age at which familial aneurysms arise tends to cluster, screening should start at the beginning of the decade in which the index subarachnoid hemorrhage occurred in the family member. The literature supports surveillance of intracranial aneurysms with CTA or MRA in individuals with known unruptured intracranial aneurysm or previously treated intracranial aneurysms. The literature varies in recommended frequency of screening or surveillance (e.g., every five to ten years) but does recommend annually imaging for an individual previously treated with endovascular coiling (Broderick, et al., 2009; Woo, et al, 2009; Bor, et al., 2008; Brown, et al., 2008; Wermer, et al., 2008; Suarez, et al., 2006; Wermer, et al., 2005a; Wermer, et al., 2005b; Vega, et al., 2002; Johnston, et al., 2002; Magnetic Resonance Angiography in Relatives of Patients with Subarachnoid Hemorrhage Study Group [The], 1999).

American Heart Association (AHA): The AHA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage (SAH) (Bederson, et al. 2009) states "Screening of certain high-risk populations for unruptured aneurysms is of uncertain value (Class IIb); advances in noninvasive imaging may be used for screening, but catheter angiography remains the gold standard when it is clinically imperative to know if an aneurysm exists." See Appendix B for ACC/AHA Definitions of Classification.

Thoracic/Abdominal

CTA/CTV is also a useful modality for thoracic and abdominal vascular imaging. The American College of Cardiology (Hendel, et al., 2006) states that CTA is appropriate for evaluation of suspected aortic dissection or thoracic aortic aneurysm and for evaluation of suspected pulmonary embolism. CTA may aid in diagnosis and surgical planning, and may sometimes obviate the need for conventional or digital angiography (ICSI, 2009; Gluecker, et al., 2008; Hendel, et al., 2006; Stein, et al., 2006; Hogg, et al., 2006; Fraioli, et al., 2006; Reinartz, et al., 2004; Radan, et al., 2004).

Peripheral Arterial Disease

CTA/CTV is indicated in peripheral arterial disease (PAD). CTA is an accurate and reliable noninvasive alternative to digital subtraction angiography in the assessment of aortoiliac and lower extremity arteries in patients with PAD, including work-up to evaluate a potential revascularization procedure (ICSI, 2009; Met, et al., 2009; Ouwendijk, et al., 2008; Kock, et al., 2005; Ouwendijk, et al., 2005; Willmann, et al., 2005; Adriaensen, et al., 2004).

American College of Cardiology/American Heart Association (ACC/AHA): The ACC/AHA Practice Guidelines for the Management of Patients with Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) (Hirsch, et al., 2006) include the following recommendations specific to CTA:

Lower Extremity PAD:

- CTA of the extremities may be considered to diagnose anatomic location and presence of significant stenosis in patients with lower extremity PAD (Class IIb)
- CTA of the extremities may be considered as a substitute for MRA for those patients with contraindications to MRA (Class IIb)
- Noninvasive imaging modalities, including MRA, CTA, and color flow duplex imaging, may be used in advance of invasive imaging to develop an individualized diagnostic strategic plan, including assistance in selection of access sites, identification of significant lesions, and determination of the need for invasive evaluation (Class IIa)

Renal Arterial Disease:

- Duplex ultrasonography, CTA (in individuals with normal renal function), and MRA are recommended as screening tests to establish the diagnosis of renal artery stenosis (Class I)
- When the clinical index of suspicion is high and the results of noninvasive tests are inconclusive, catheter angiography is recommended as a diagnostic test to establish the diagnosis of renal artery stenosis (Class I)

Mesenteric Arterial Disease:

- Duplex ultrasound, CTA, and gadolinium-enhanced MRA are useful initial tests for supporting the clinical diagnosis of chronic intestinal ischemia (Class I)

See Appendix B for ACC/AHA Definitions of Classification.

Congenital Vascular Abnormalities

The ACC (Hendel, et al., 2006) states that CTA is appropriate for evaluation of complex congenital heart disease, including anomalies of coronary circulation, great vessels, and cardiac chambers and valves. CTA is appropriate for imaging vascular abnormalities associated with congenital conditions such as Marfan syndrome, pulmonary sequestration, and vascular rings (Bluemke, et al., 2008; Ha, et al., 2007; Goldstein, et al., 2007; Budoff, et al., 2006; Hendel, et al., 2006; Juraszek, et al., 2006; Berbarie et al 2006).

American College of Cardiology/American Heart Association (ACC/AHA): The ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease (Warnes, et al., 2008) included these recommendation specific to CTA:

- Recommendations for Evaluation of Patients With Supravalvular, Branch, and Peripheral Pulmonary Stenosis: Patients with suspected supravalvular, branch, or peripheral pulmonary stenosis should have baseline imaging with echocardiography-Doppler plus one of the following: MR angiography, CT angiography, or contrast angiography (Class I)
- Recommendations for Coronary Arteriovenous Fistula: If a continuous murmur is present, its origin should be defined either by echocardiography, MRI, CT angiography, or cardiac catheterization (Class I)

See Appendix B for ACC/AHA Definitions of Classification.

Prior to Radiofrequency Ablation

CTA may be indicated to evaluate pulmonary veins and left atrium prior to radiofrequency ablation for atrial fibrillation or supraventricular tachycardia to help identify multidimensional anatomical landmarks.

64-slice Or Greater Coronary CTA

Note: See Appendix A for definition of pre-test probability of coronary artery disease (CAD).

The American Heart Association states that 64-slice MDCT is the current standard for coronary CT angiography and noncalcified plaque characterization based on publications to date (Budoff, et al., 2006). Studies in the peer-reviewed scientific literature support the use of at least 64-slice for coronary artery CTA (Hausleiter, et al., 2007; Sun, et al., 2006).

Hoffmann et al. (2009) performed urgent CTA in 368 symptomatic individuals with low and intermediate pre-test probability of CAD and normal ECG. There were eight (2.1%) patients who proved to have an acute MI, and a further 23 (6.3%) had a final diagnosis of acute coronary syndrome. The remaining 337 patients (91.6%) had no evidence of active myocardial ischemia at the time of hospital discharge. Over a mean follow-up of 6.2 months, none of these 337 patients had a major cardiac event. The authors noted that early coronary CTA in the emergency department may significantly improve patient management by aiding clinical decision making, specifically early discharge of subjects at low to intermediate likelihood of acute coronary syndrome without CAD.

Budoff et al. (2008a) directly compared CTA and invasive angiography in the 'Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography' (ACCURACY) trial. There were 230 symptomatic patients with intermediate pre-test probability of CAD referred with chest pain for invasive angiography who also underwent CTA. The sensitivity, specificity, and positive and negative predictive values to detect $\geq 50\%$ stenosis were 95%, 83%, 64%, and 99%, respectively. Budoff et al. stated that based upon the high accuracy of CTA, it can replace invasive angiography in the population studied. Meijboom

et al. (2008) also directly compared CTA and invasive angiography in 360 symptomatic individuals with intermediate and high pre-test probability of CAD. The sensitivity, specificity, and positive and negative predictive values to detect $\geq 50\%$ stenosis were 99%, 64%, 86%, and 97%, respectively. Meijboom also agreed that CTA's high accuracy makes it reliable for ruling out CAD in anginal syndromes.

Miller et al. (2008) also directly compared CTA and invasive angiography in the 'Coronary Artery Evaluation Using 64-Row Multidetector Computed Tomography Angiography' (CORE 64) study. A total of 291 symptomatic patients with intermediate and high pre-test probability of CAD symptomatic patients referred for invasive angiography underwent CTA also. The sensitivity, specificity, and positive and negative predictive values to detect $\geq 50\%$ stenosis were 85%, 90%, 91%, and 83%, respectively. The authors stated that CTA has powerful discriminative ability to identify, among symptomatic patients, those with and those without coronary obstruction. The authors noted that given the positive predictive value of 91% and the negative predictive value of 83%, multidetector CTA "cannot replace conventional coronary angiography" in this population of patients at present.

Budoff et al. (2008b) reported on 493 patients, the majority of which had an intermediate pre-test probability of CAD who underwent CTA. CTA was requested for indications including chest pain, shortness of breath, abnormal or equivocal stress test, cardiomyopathy, congestive heart failure, or syncope. Of the 493 cases evaluated, 157 (32%) cases were reported to be normal, 204 patients were classified as having nonobstructive disease (41%), 93 patients were defined to have obstructive CAD (19%), and 39 cases were inconclusive (8%). The authors stated that a strategy of selective cardiac catheterization may substantially decrease unnecessary diagnostic cardiac catheterizations.

Mowatt et al. (2008a) conducted a systematic review and meta-analysis to assess the accuracy of 64-slice CTA compared with conventional coronary angiography in the diagnosis and assessment of CAD. Mowatt et al. included 28 studies, including randomized controlled trials, non-randomized comparative studies and case series. Mowatt et al. concluded that given the high sensitivity and negative predictive value, the main role of CTA may be to rule out significant CAD, and thereby reduce the need for invasive coronary angiography. There are several clinical situations where this may be particularly useful. In patients with a very low probability of CAD it is unlikely that CTA would be recommended, particularly given the radiation doses involved. Mowatt et al. noted that likewise, when the probability of CAD is high conventional angiography is likely to remain the investigation of choice in the majority of patients. However, very many patients fall into an intermediate category where the diagnosis of CAD remains uncertain following clinical assessment and simple non-invasive testing. Currently, this may necessitate either myocardial perfusion scanning or invasive coronary angiography. It seems likely that CTA may have an increasing role in this setting.

Husmann et al. (2008) evaluated 88 consecutive patients with suspected CAD to compare the diagnostic accuracy of 64-slice CTA in groups of patients with low, intermediate, and high risk for CAD events. The patients were referred for invasive angiography and CTA because of dyspnea ($n = 22$), typical angina pectoris ($n = 31$), or atypical chest pain ($n = 19$), or to preoperatively rule out CAD ($n = 16$). Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy were calculated for low, intermediate and high risk per patient. Per patient accuracy for low, intermediate and high risk were 82.4%, 89.7% and 92.0%, respectively. The authors noted that CTA would have avoided unnecessary invasive angiography in 56%, 41%, and 24% of patients in the groups with low, intermediate, and high risk for CAD events. The authors noted that this would not be achieved at the cost of falsely sending many patients to invasive angiography, as the high number of avoided invasive angiography by far outweighs the few false-positive values.

Meijboom et al. (2007) evaluated the diagnostic performance and clinical usefulness of 64-slice CTA in 254 symptomatic patients with various estimated pre-test probabilities of CAD. The analysis comprised 105 (43%) patients with a high estimated pre-test probability for CAD, 83 (33%) patients with an intermediate, and 66 (26%) patients with a low estimated pre-test probability for CAD. Comparison between CTA and coronary angiography was performed. The diagnostic performance of CTA for the detection of significant coronary artery stenoses as defined by coronary angiography is presented as sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). By patient:

- High pre-test probability: sensitivity 98%, specificity 74%, PPV 93% and NPV 89%
- Intermediate pre-test probability: sensitivity 100%, specificity 84%, PPV 80% and NPV 100%
- Low pre-test probability: sensitivity 100%, specificity 93%, PPV 75% and NPV 100%

The authors noted that the pre-test probability of CAD impacts the diagnostic performance of CTA. The authors concluded that 64-slice CTA is useful in symptomatic patients with a low or intermediate estimated pre-test probability of having significant CAD, and a negative CT scan reliably rules out the presence of significant CAD.

In a prospective observational study, Cademartiri et al. (2007) recruited 72 patients with a low or intermediate cardiovascular risk atypical chest pain (26/72; 36.1%) or exertional angina (46/72; 63.9%), and positive, doubtful or inconclusive stress electrocardiogram (ECG) who were scheduled for invasive coronary angiography, to determine the presence and extent of coronary disease. CTA and invasive angiography (reference standard) were compared. Results indicated that diagnostic accuracy values were above all high as regards sensitivity and negative predictive value (~100%). Specificity and particularly positive predictive value, on the other hand, were lower as a result of the relatively low disease prevalence among the population. The number of false positives had a particularly evident impact on the evaluation per segment (n=15) and per vessel, whereas it was not particularly evident in the evaluation per patient (n=1). The authors stated that if CTA had been used as a gatekeeper for coronary angiography, invasive angiography would have been performed in one patient without significant stenoses, whereas all patients with stenoses would have been correctly referred for invasive angiography. No patient with significant coronary disease would have been misclassified as not having significant coronary stenoses. The authors concluded that noninvasive 64-slice CTA is a technique with a high diagnostic accuracy in the detection of significant coronary stenoses in patients with atypical pain or stable angina and low to intermediate risk.

In trying to determine the ability of 64-slice CTA to rule out high-grade coronary stenoses in patients with a low to moderate pre-test probability of significant CAD, Schlosser et al. (2007) studied 61 patients with a suspicion of CAD on the basis of atypical angina or ambiguous findings in noninvasive stress testing and a class II indication for ICA. On a coronary segmental basis, 28 false-positive and 0 false-negative findings resulted in a sensitivity of 100%, a specificity of 96.8%, a PPV of 54.8%, and an NPV of 100%. The diagnostic accuracy was 96.9%. The authors concluded that 64-slice CTA “reliably detects significant coronary stenosis in patients with a low to moderate pre-test probability of significant CAD. In the presence of plaque and severe calcifications, CTA can result in an overestimation of stenoses and therefore does not allow ruling out of significant stenoses. However, CTA appears to be helpful in the selection of patients who need to undergo ICA.”

Technology Assessments: The Health Technology Assessment (HTA) Program, part of the United Kingdom (UK) National Institute for Health Research (NIHR), published a Health Technology Assessment (Mowatt, et al., 2008b). Mowatt et al. conducted a systematic review and evaluated the clinical effectiveness, in different patient groups, of the use of 64-slice or higher CTA, instead of invasive angiography, for diagnosing people with suspected CAD and assessing people with known CAD. The diagnostic accuracy and prognostic studies enrolled over 2500 and 1700 people, respectively. Mowatt et al. reports that the technical factors that enhance image quality in 64-slice CT also result in a higher radiation dose, although the use of electrocardiogram (ECG)-dependent dose modulation can reduce this by 30–50%. The proportion of invasive angiography that could be replaced by 64-slice CT is currently uncertain. Reduction in invasive angiography would be mainly at the diagnostic end of the pathway, in both elective assessment of chest pain of possibly anginal origin, and assessment of suspected acute coronary syndromes in some patients with normal or equivocal ECGs and negative troponin tests. In the emergency situation, some hospital admissions might be avoided. However, to do so, 64-slice CT would need to be readily available, ideally on a 24-hour basis, which is unlikely to be the case in most hospitals. Mowatt et al. also notes that some perfusion studies could also be replaced by 64 slice CT angiography. In summary, the main value of 64-slice CT may at present be to rule out significant CAD. It is unlikely to replace CA in assessment for revascularization of patients, particularly as angiography and angioplasty are often done on the same occasion.

The California Technology Assessment Forum (CTAF) published CTA in the Diagnosis of Coronary Artery Stenosis and for the Evaluation of Acute Chest Pain (October 2007). The CTAF notes that cardiac CTA is being evaluated for use in the diagnosis of coronary artery stenosis or for the evaluation of acute chest pain. Although several studies have assessed diagnostic accuracy of CTA (e.g., sensitivity and specificity), fewer have assessed clinical outcomes or compared CTA to conventional diagnostic strategies. Additional limitations include the inability of CTA to accurately assess all the coronary arteries (a certain percentage of the arteries are read as indeterminate which then leads to additional diagnostic testing), and the risks of radiation exposure and nephrotoxicity. CTAF states:

- CTA as a substitute for coronary angiography for the diagnosis of coronary artery stenosis does not meet the CTAF criteria for safety, efficacy and improvement in health outcomes.

- CTA in the evaluation of acute chest pain in the ER does not meet CTAF criteria for safety, efficacy and improvement in health outcomes.

The Health Technology Assessment (HTA) Program published a Health Technology Assessment (Collins, et al., 2007). Collins et al. conducted a systematic review of duplex ultrasound, MRA and CTA for the diagnosis and assessment of symptomatic, lower limb PAD. Collins et al. concluded that contrast enhanced (CE) MRA has the best overall diagnostic accuracy of the three index tests evaluated. Where available, CE MRA may be a viable alternative to contrast angiography. The overall diagnostic performance of CTA in detecting stenoses of 50% or more was inferior to CE MRA. However, the results for the performance of CTA to image arteries of the foot appear promising. As the assessment of PAD is a relatively new application for this technology, there was insufficient evidence to evaluate the usefulness of CTA in this area.

The Medicare Coverage Advisory Commission published a technology assessment on noninvasive imaging for CAD (Patel, et al., 2007). A review of the available scientific evidence through 2005 was conducted for direct noninvasive imaging tests for CAD. Specifically, a search for 16 (and higher) CTA and 1.5 Tesla MRA to evaluate for stenosis in native coronary arteries, resulted in 123 articles. The authors concluded that “the evidence base for noninvasive direct coronary imaging technologies is currently inadequate for routine use in the diagnosis and management of CAD. Although the sensitivity and specificity of noninvasive direct coronary imaging technologies on a per patient basis look promising, specifically with 64-slice CTA, current studies are limited by number of studies available to determine if the data are generalizable to the U.S. Medicare population. Evaluation of noninvasive technologies in appropriate clinical situations, in patients with well-defined risk, at multiple centers is required. In addition, studies evaluating these technologies and their resultant effects on both clinical management and patient outcomes are lacking and needed. The ability to noninvasively image the coronary arteries provides the potential to leap into an age of improved early diagnosis and therapy for CAD. The burden of proof lies on the cardiovascular community to ensure that patients, payers, and clinicians realize this potential.”

The Blue Cross Blue Shield Association Technology Evaluation Center (TEC) Technology Assessment ‘Contrast-Enhanced Cardiac Computed Tomographic Angiography in the Diagnosis of Coronary Artery Stenosis or for Evaluation of Acute Chest Pain’ (August, 2006) concluded that the available evidence is inadequate to determine whether CTA improves the net health outcome or is as beneficial as established alternatives for diagnosis of coronary artery stenosis or for evaluation of acute chest pain in the ER. CTA as a substitute for coronary angiography in the diagnosis of coronary artery stenosis does not meet criteria. CTA in the evaluation of acute chest pain in the emergency room also does not meet criteria.

Professional Societies/Organizations (Coronary CTA)

American College of Cardiology (ACC)/American College of Radiology (ACR)

Note: See Appendix A for definition of pre-test probability of CAD.

The ACC, ACR, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology published Appropriateness Criteria for Cardiac Computed Tomography and Cardiac Magnetic Resonance Imaging in October 2006 (Hendel, et al., 2006). Some include:

- For the detection of CAD in symptomatic patients, evaluation of chest pain syndrome, CTA is: Appropriate, if intermediate pre-test probability of CAD and ECG uninterpretable or unable to exercise
- For the detection of CAD in symptomatic patients, evaluation of intracardiac structures, CTA is: Appropriate, if evaluation of suspected coronary anomalies
- For the detection of CAD in symptomatic patients, acute chest pain, CTA is: Appropriate, if intermediate pre-test probability of CAD and no ECG changes and serial enzymes negative
- For Detection of CAD with Prior Test Results, Evaluation of Chest Pain Syndrome, CTA is: Appropriate, if uninterpretable or equivocal stress test (exercise, perfusion, or stress echo)
- For Morphology, CTA is:
 - Appropriate, if assessment of complex congenital heart disease, including anomalies of coronary circulation, great vessels, and cardiac chambers and valves
 - Appropriate, if evaluation of coronary arteries in patients with new onset heart failure to assess etiology

- For Evaluation of Aortic and Pulmonary Disease, CTA is:
 - Appropriate, if evaluation of suspected aortic dissection or thoracic aortic aneurysm
 - Appropriate, if evaluation of suspected pulmonary embolism
- For the detection of CAD, post-revascularization (PCI or CABG), evaluation of chest pain syndrome, CTA is:
 - Uncertain, if evaluation of bypass grafts and coronary anatomy
 - Uncertain, if history of percutaneous revascularization with stents
- For the detection of CAD, post-revascularization (PCI or CABG), asymptomatic, CTA is
 - Inappropriate, if evaluation of bypass grafts and coronary anatomy and less than five years after CABG
 - Inappropriate, if evaluation of bypass grafts and coronary anatomy and greater than or equal to five years after CABG
 - Inappropriate, if evaluation for in-stent restenosis and coronary anatomy after PCI

American Heart Association (AHA)

The AHA published a Scientific Statement “Noninvasive Coronary Artery Imaging: Magnetic Resonance Angiography and Multidetector Computed Tomography Angiography” (Bluemke, et al., 2008). The AHA states that the chief advantages of coronary CTA compared with MRA are wider availability, higher spatial resolution, and more consistent, shorter examinations with better patient adherence. Advantages associated with coronary MRA are a lack of ionizing radiation and a lack of administration of iodinated contrast material. Both tests are presently suboptimal for patients with atrial fibrillation and other arrhythmias, and image quality may be further reduced by high body mass. The AHA notes that specific recommendations for use of these technologies are expected to change along with advances in scanner hardware and software. At present, the following general statements represent the consensus opinions of the writing group:

1. Neither coronary CTA nor MRA should be used to screen for CAD in patients who have no signs or symptoms suggestive of CAD. (Class III)
2. No multivendor trial data are available for coronary MDCT CTA or for present whole-heart coronary MRA. Thus, the applicability of these methods beyond the reporting research centers is unknown. Ideally, both multivendor and additional multicenter validation of these methods should be performed. (Class I)
3. The potential benefit of noninvasive coronary angiography is likely to be greatest and is reasonable for symptomatic patients who are at intermediate risk for CAD after initial risk stratification, including patients with equivocal stress-test results. (Class IIa)
 Diagnostic accuracy favors coronary CTA over MRA for these patients. (Class I)
 Concerns regarding radiation dose limit the use of coronary CTA in high-risk patients who have a very low pre-test likelihood of coronary stenoses; patients with a high pre-test likelihood of coronary stenoses are likely to require intervention and invasive catheter angiography for definitive evaluation; thus, CTA is not recommended for those individuals. (Class III)
 Pronounced coronary calcification may negatively impact interpretability and accuracy of coronary CTA and thus, the usefulness of CTA is uncertain in these individuals. (Class IIb)
4. Anomalous coronary artery evaluation can be performed by either CTA or MRA; radiation-protection concerns indicate that MRA is preferred when it is available. (Class IIa)
5. Reporting of coronary CTA and MRA results should describe any limitations to the technical quality of the examination and the size of the vessels, descriptions of coronary anomalies, coronary stenosis, and significant noncardiac findings within the field of view. (Class I)
6. Continued research in cardiac CT and MR imaging is encouraged to determine the potential of these noncatheter-based modalities to detect, characterize, and measure atherosclerotic plaque burden, as well as its change over time or as the result of therapy. (Class I).
 See Appendix B for ACC/AHA Definitions of Classification.

American Heart Association (AHA)

The AHA published a scientific statement on assessment of CAD by cardiac computed tomography in October 2006 (Budoff, et al., 2006). Recommendations specific to CTA include:

- Suspected CAD: CT coronary angiography is reasonable for the assessment of obstructive disease in symptomatic patients (Class IIa). Use of CT angiography in asymptomatic persons as a screening test for atherosclerosis (noncalcific plaque) is not recommended (Class III)
- Follow-Up of Percutaneous Coronary Intervention: Imaging of patients to follow-up stent placement cannot be recommended (Class III).
- Follow-Up After Bypass Surgery: In most studies, the accuracy to detect bypass occlusion approached 100%. Clinically, however, it might be reasonable in most cases to not only assess the patency of the bypass graft but also the presence of coronary stenoses in the course of the bypass graft or at the anastomotic site, as well as in the native coronary artery system (Class IIb). This is more difficult, owing to the smaller caliber of these vessels, the presence of artifacts caused by metal clips, and the often pronounced coronary calcification.
- Anomalous Coronary Arteries: It reasonable to use CTA as one of the first-choice imaging modalities in the workup of known and suspected coronary anomalies (Class IIa). See Appendix B for ACC/AHA Definitions of Classification.

European Society of Cardiology

A Writing Group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuclear Cardiology published a report on Cardiac Computed Tomography (Schroeder, et al., 2008). The following recommendations addressed CTA:

Detection of Coronary Artery Stenoses: the clinical application of coronary CTA to detect or rule out coronary artery stenoses seems most beneficial and, according to current data, can be recommended in patients with intermediate risk of CAD in whom the clinical presentation— stable or with acute symptoms—mandates the evaluation of possible underlying CAD. A similar conclusion was reached in an expert consensus document on ‘appropriate’ indications for cardiac CT and cardiac magnetic resonance imaging (Hendel, et al., 2006). The use of coronary CTA should be restricted to patients in whom diagnostic image quality can be expected (e.g., absence of arrhythmias), and scans need to be expertly performed and interpreted.

Coronary Stent Imaging: Although in single, carefully selected cases (e.g., large diameter stents in a proximal vessel segment, low and stable heart rate, and absence of excessive image noise) coronary CTA may be a possibility to rule out in-stent restenosis, routine application of CT to assess patients with coronary stents can currently not be recommended. Visualization of the stent lumen is often affected by artifacts, and especially the positive predictive value is low.

Coronary Artery Bypass Grafts: Although the clinical application of CTA may be useful in very selected patients in whom only bypass graft assessment is necessary (e.g., failed visualization of a graft in invasive angiography), the inability to reliably visualize the native coronary arteries in patients post-CABG poses severe restrictions to the general use of CTA in post-bypass patients.

Coronary Artery Anomalies: The robust visualization and classification of anomalous coronary arteries make CTA a first-choice imaging modality for the investigation of known or suspected coronary artery anomalies. Radiation dose must be considered often in the young patients, and measures to keep dose as low as possible must be employed.

Non-calcified Plaque: The fact that there is currently a lack of prospective clinical data that would support the use of contrast-enhanced CTA for the assessment of non-stenotic plaque does not allow clinical applications in asymptomatic individuals for the purpose of risk stratification. However, the tremendous potential of CTA for visualization and characterization of coronary plaques must be recognized and further research is strongly supported.

Left and Right Ventricular Function: Although CT imaging allows accurate assessment of left and right ventricular function, CT examinations will in most cases not be performed specifically for that purpose. Other diagnostic tests without radiation exposure or the need for contrast injection (i.e. echocardiography) are the methods of choice. However, it should be noted that ventricular function is adjunct information that can be obtained from standard coronary CTA investigations without altering the image acquisition protocol, and the ability of CT to provide accurate right ventricular assessment might be useful in several clinical conditions including congenital heart disease, carcinoid heart disease, or prior to lung transplantation.

North American Society of Cardiac Imaging and the European Society of Cardiac Radiology

The NASCI/ESCR published a consensus/position statement on the use of multidetector computed tomography for the assessment of acute chest pain. Stillman et al. (2007) states, "specific emergency department chest-pain protocols in which the differential diagnosis includes a coronary artery etiology can be divided into two groups. If the patient is stable and primary clinical suspicion is angina, a dedicated cardiac CTA may be sufficient. Alternatively, if the clinical evaluation is less specific and differential considerations include angina and other serious causes of acute chest pain, a comprehensive or global evaluation may be deemed appropriate. The latter protocol is also termed the triple threat or triple rule-out protocol."

American College of Radiology (ACR)

The ACR Practice Guideline for the Performance and Interpretation of CTA (2006) states that CTA "is a proven and useful procedure for the detection and characterization of vascular diseases and of vascular anatomy relevant to the treatment of extravascular disorders. CTA may be used as the primary modality for detecting disease or as an adjunctive tool for better characterizing known disease or assessing changes in disease state over time." It notes that CTA "is primarily performed for assessment of the heart, arteries, or veins of the body." The Practice Guideline states that indications for CTA of cardiac and extracardiac vessels include, but are not limited to, the diagnosis, characterization, and/or surveillance of:

- arterial and venous aneurysms
- atherosclerotic occlusive disease
- nonatherosclerotic, noninflammatory vasculopathy
- traumatic injuries to arteries and veins
- arterial dissection and intramural hematoma
- arterial and venous thromboembolism
- congenital vascular anomalies
- vascular anatomic variants
- vascular interventions (percutaneous and surgical)
- vasculitis and collagen vascular diseases
- vascular infection

Radiation Exposure

The Prospective Multicenter Study On Radiation Dose Estimates Of Cardiac CT Angiography In Daily Practice I (PROTECTION I) (Hausleiter, et al., 2009) was an observational study involving 1965 patients undergoing coronary CTA at 50 sites. Outcomes measured included the volume CT dose index (CTDI_{vol}) and dose-length product (DLP). The researchers commented on the variability in dose levels observed in the study, and stated that improved education of physicians and technicians performing coronary CTA on dose-saving strategies might be considered to keep the radiation dose "as low as reasonably achievable" in every patient undergoing coronary CTA.

The AHA published a Science Advisory on Ionizing Radiation in Cardiac Imaging (Gerber, et al., 2009) that makes general recommendations for the safe use of cardiac imaging that relies on ionizing radiation. The ACC/AHA published a Clinical Competence Statement on Vascular Imaging with Computed Tomography and Magnetic Resonance (Kramer, et al., 2007). Kramer et al. noted that radiation comes from two sources for CTA; the iodinated contrast material and from exposure to ionizing radiation. It is imperative that practitioners of CTA understand the potential risks of ionizing radiation exposure from the test and balance these risks against the potential benefits. Patient doses for MDCT acquisition should be set at the lowest values that are consistent with satisfactory image quality. There are differences in radiation exposure depending on the vascular application.

Einstein et al. (2007) aimed to determine the lifetime attributable risk (LAR) of cancer incidence associated with radiation exposure from a single coronary CTA study and to determine how this risk is influenced by patient age, sex, and scan protocol. The authors determined equivalent doses to individual organs from CTA using Monte Carlo simulations, and then determined cancer risks from these doses using the approach proposed in the National Academies' Biological Effects of Ionizing Radiation 7th Report (BEIR VII). Lifetime cancer risk estimates for standard cardiac scans varied from 1 in 143 for a 20-year-old woman to 1 in 3261 for an 80-year-old man. Use of simulated electrocardiographically controlled tube current modulation (ECTCM) decreased these risk estimates to 1 in 219 and 1 in 5017, respectively. The authors state that their results suggest that coronary CTA should be used particularly cautiously in the evaluation of young individuals, especially women,

for whom alternative diagnostic modalities that do not involve the use of ionizing radiation should be considered, such as stress electrocardiography, echocardiography, or magnetic resonance imaging. If CTA is considered as an alternative to invasive coronary angiography, the risks and benefits of each test require consideration. While radiation doses are typically greater in coronary CTA, invasive angiography is associated with a 1.7% risk of major complications, including vascular complications, stroke, and death in 0.11% of patients (Scanlon, et al., 1999). The authors concluded that the estimates derived from their simulation models suggest that use of 64-slice coronary CTA is associated with a non-negligible LAR of cancer. The state that this risk varies markedly; it is considerably greater for women, younger patients, and for combined cardiac and aortic scans, especially in men; and decreases with ECTCM. The authors state that careful selection of patients for CT and the careful optimization of scan protocol in patients referred for testing can help to minimize cancer risk.

Summary

There is sufficient evidence in the peer-reviewed scientific literature supporting the use of noninvasive multidetector-row computed tomography angiography (CTA) and venography (CTV) as a vascular imaging technique that can be performed rapidly and safely for the assessment of many vascular diseases. Studies have demonstrated the high degree of accuracy of CTA compared to invasive angiography for imaging of vessels of the head, neck, thorax, abdomen and extremities. CTA can aid in evaluation of suspected pulmonary embolism and imaging vascular abnormalities associated with congenital conditions. CTA is useful in some population subsets for screening and surveillance of intracranial aneurysms.

There is sufficient evidence in the peer-reviewed scientific literature to support the use of 64-slice CTA as an adjunct to other testing in specific cardiac population subsets with low and intermediate pre-angiography probability of CAD. The literature regarding CTA performed on a multidetector-row scanner with less than 64 slices is not consistent, as is 64-slice literature in demonstrating high accuracy for the detailed diagnosis of CAD. Current literature does not provide sufficient evidence to support a role for CTA for asymptomatic population coronary artery disease (CAD) screening. Although less invasive than catheter-based coronary angiography, CTA still involves significant radiation exposure and the potential for iodinated contrast-related reactions. Practitioners of CTA should understand the potential risks of ionizing radiation exposure from the test and balance these risks against the potential benefits.

Coding/Billing Information

Note: This list of codes may not be all-inclusive.

Covered when medically necessary:

CPT®* Codes	Description
70496	CTA HEAD, with contrast material(s), including noncontrast images, if performed and image post-processing.
70498	CTA NECK, with contrast material(s), including noncontrast images, if performed and image post-processing.
71275	CTA CHEST, (non-coronary), with contrast material(s), including noncontrast images, if performed and image post-processing.
72191	CTA PELVIS, with contrast material(s), including noncontrast images, if performed and image post-processing.
73206	CTA Upper Extremity, with contrast material(s), including noncontrast images, if performed and image post-processing.
73706	CTA Lower Extremity, with contrast material(s), including noncontrast images, if performed and image post-processing.
74175	CTA ABDOMEN, with contrast material(s), including noncontrast images, if performed and image post-processing.
75574	Computed tomographic angiography, heart, coronary arteries and bypass grafts (when present), with contrast material, including 3D image postprocessing (including evaluation of cardiac structure and morphology, assessment of cardiac function, and evaluation of venous structures, if performed)

75635	CTA ABDOMINAL AORTA and bilateral iliofemoral lower extremity runoff, with contrast material(s), including noncontrast images, if performed and image post-processing.
0146T	Computed tomography, heart, with contrast material(s), including noncontrast images, if performed, cardiac gating and 3D image postprocessing; computed tomographic angiography of coronary arteries (including native and anomalous coronary arteries, coronary bypass grafts), without quantitative evaluation of coronary calcium (code deleted 12/31/2009)
0147T	Computed tomography, heart, with contrast material(s), including noncontrast images, if performed, cardiac gating and 3D image postprocessing; computed tomographic angiography of coronary arteries (including native and anomalous coronary arteries, coronary bypass grafts), with quantitative evaluation of coronary calcium (code deleted 12/31/2009)
0148T	Computed tomography, heart, with contrast material(s), including noncontrast images, if performed, cardiac gating and 3D image postprocessing; cardiac structure and morphology and computed tomographic angiography of coronary arteries (including native and anomalous coronary arteries, coronary bypass grafts), without quantitative evaluation of coronary calcium (code deleted 12/31/2009)
0149T	Computed tomography, heart, with contrast material(s), including noncontrast images, if performed, cardiac gating and 3D image postprocessing; cardiac structure and morphology and computed tomographic angiography of coronary arteries (including native and anomalous coronary arteries, coronary bypass grafts), with quantitative evaluation of coronary calcium (code deleted 12/31/2009)

ICD-9-CM Diagnosis Codes	Description
411.1 [†]	Intermediate coronary syndrome
413.0-413.9 [†]	Angina Pectoris
414.01 [†]	Coronary atherosclerosis of native coronary artery
414.9 [†]	Unspecified chronic ischemic heart disease
415.11-415.19	Pulmonary embolism
428.0 [†]	Congestive heart failure, unspecified
428.1 [†]	Left heart failure
428.9 [†]	Unspecified heart failure
429.2 [†]	Unspecified cardiovascular disease
430	Subarachnoid hemorrhage
431	Intracerebral hemorrhage
432.0-432.9	Other intracranial hemorrhage
433.00 – 433.91	Occlusion and stenosis of precerebral arteries
434.00 – 434.91	Occlusion of cerebral arteries
435.0 – 435.9	Transient cerebral ischemia
436	Acute but ill-defined cerebrovascular disease
437.0 – 437.9	Other and ill-defined cerebrovascular disease
440.0 – 440.9	Atherosclerosis
441.0 – 441.9	Aortic aneurysm and dissection
442.0 – 442.9	Other aneurysm
443.0 – 443.9	Other peripheral vascular disease
444.0 – 444.9	Arterial embolism and arthrosis
746.0-746.9	Other congenital anomalies of the heart
747.0 – 747.9	Other congenital anomalies of the circulatory system

786.50 [†]	Unspecified chest pain
---------------------	------------------------

[†] **Note:** These indications are covered only if performed using 64-slice CT

Experimental/Investigational/Unproven/Not Covered:

ICD-9-CM Diagnosis Codes	Description
V45.81	Postprocedural aortocoronary bypass status
V81.0	Screening for ischemic heart disease

***Current Procedural Terminology (CPT®) © 2010 American Medical Association: Chicago, IL.**

References

1. Adriaensen ME, Kock MC, Stijnen T, van Sambeek MR, van Urk H, Pattynama PM, Myriam Hunink MG. Peripheral arterial disease: therapeutic confidence of CT versus digital subtraction angiography and effects on additional imaging recommendations. *Radiology*. 2004 Nov;233(2):385-91.
2. American College of Radiology Practice Guideline for the performance and interpretation of CTA (CTA) Amended 2006. Accessed June 2009. Available at URL address: http://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/dx/cardio/ct_angiography.aspx
3. American College of Radiology. Computed Tomographic Angiography. July 2001. Previously, but no longer available at URL: http://www.acr.org/s_acr/doc.asp?TrackID=&SID=1&DID=11217&CID=733&VID=2&RTID=0&CIDQS=&Taxonomy=False&specialSearch=False
4. Andreini D, Pontone G, Pepi M, Ballerini G, Bartorelli AL, Magini A, et al. Diagnostic accuracy of multidetector computed tomography coronary angiography in patients with dilated cardiomyopathy. *J Am Coll Cardiol*. 2007 May 22;49(20):2044-50.
5. Bash S, Villablanca JP, Jahan R, Duckwiler G, Tillis M, Kidwell C, et al. Intracranial vascular stenosis and occlusive disease: evaluation with CTA, MR angiography, and digital subtraction angiography. *AJNR Am J Neuroradiol*. 2005 May;26(5):1012-21.
6. Bederson JB, Connolly ES Jr, Batjer HH, Dacey RG, Dion JE, American Heart Association, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. *Stroke*. 2009 Mar;40(3):994-1025. Epub 2009 Jan 22.
7. Barbarie R, Dockery W, Johnson K, Rosenthal R, Stoler R, et al. Use of Multislice Computed Tomographic Coronary Angiography for the Diagnosis of Anomalous Coronary Arteries. *Am J Cardiol* 2006;98:402– 406.
8. Bluemke DA, Achenbach S, Budoff M, Gerber TC, Gersh B, Hillis LD, et al. Noninvasive Coronary Artery Imaging. Magnetic Resonance Angiography and Multidetector Computed Tomography Angiography. A Scientific Statement From the American Heart Association Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention, and the Councils on Clinical Cardiology and Cardiovascular Disease in the Young. *Circulation*. 2008 Jun 27. [Epub ahead of print]

9. Bor AS, Rinkel GJ, Adami J, Koffijberg H, Ekbom A, Buskens E, et al. Risk of subarachnoid haemorrhage according to number of affected relatives: a population based case-control study. *Brain*. 2008 Oct;131(Pt 10):2662-5. Epub 2008 Sep 26.
10. Brindis RG, Douglas PS, Hendel RC, American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group; American Society of Nuclear Cardiology; American Heart Association. ACCF/ASNC appropriateness criteria for single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI): a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group and the American Society of Nuclear Cardiology endorsed by the American Heart Association. *J Am Coll Cardiol*. 2005 Oct 18;46(8):1587-605. Review. Erratum in: *J Am Coll Cardiol*. 2005 Dec 6;46(11):2148-50.
11. Broderick JP, Brown RD Jr, Sauerbeck L, Hornung R, Huston J 3rd, FIA Study Investigators, et al. Greater rupture risk for familial as compared to sporadic unruptured intracranial aneurysms. *Stroke*. 2009 Jun;40(6):1952-7. Epub 2009 Feb 19.
12. Brown RD Jr, Huston J, Hornung R, Foroud T, Kallmes DF, Kleindorfer D, et al. Screening for brain aneurysm in the Familial Intracranial Aneurysm study: frequency and predictors of lesion detection. *J Neurosurg*. 2008 Jun;108(6):1132-8.
13. Budoff MJ, Achenbach S, American Heart Association Committee on Cardiovascular Imaging and Intervention; American Heart Association Council on Cardiovascular Radiology and Intervention; American Heart Association Committee on Cardiac Imaging, Council on Clinical Cardiology, et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. *Circulation*. 2006 Oct 17;114(16):1761-91.
14. Budoff MJ, Dowe D, Jollis JG, Gitter M, Sutherland J, Halamert E, et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial. *J Am Coll Cardiol*. 2008a Nov 18;52(21):1724-32
15. Budoff MJ, Gopal A, Gul KM, Mao SS, Fischer H, Oudiz RJ. Prevalence of obstructive coronary artery disease in an outpatient cardiac CT angiography environment. *Int J Cardiol*. 2008b Sep 16;129(1):32-6. Epub 2007 Jul 24.
16. Blue Cross Blue Shield Association. Technology Evaluation Center (TEC) Assessment. Contrast-Enhanced Cardiac Computed Tomographic Angiography in the Diagnosis of Coronary Artery Stenosis or for Evaluation of Acute Chest Pain. Volume 21, No. 5. August 2006. Accessed June 2009. Available at URL address: http://www.bcbs.com/blueresources/tec/vols/21/21_05.html
17. Cademartiri F, Maffei E, Palumbo A, Malagò R, Alberghina F, Aldrovandi A, et al. Diagnostic accuracy of 64-slice computed tomography coronary angiography in patients with low-to-intermediate risk. *Radiol Med (Torino)*. 2007 Oct;112(7):969-81.
18. California Technology Assessment Forum (CTAF). CTA in the Diagnosis of Coronary Artery Stenosis and for the Evaluation of Acute Chest Pain. October 17, 2007. Accessed July 2009. Available at URL address <http://www.ctaf.org/content/general/detail/768>
19. Chappell ET, Moure FC, Good MC. Comparison of computed tomographic angiography with digital subtraction angiography in the diagnosis of cerebral aneurysms: a meta-analysis. *Neurosurgery*. 2003;52(3):624-631.

20. Chen W, Yang Y, Xing W, Qiu J, Peng Y. Sixteen-row multislice computed tomography angiography in the diagnosis and characterization of intracranial aneurysms: comparison with conventional angiography and intraoperative findings. *J Neurosurg*. 2008 Jun;108(6):1184-91.
21. Collins R, Cranny G, Burch J, Aguiar-Ibáñez R, Craig D, Wright K, et al. A systematic review of duplex ultrasound, magnetic resonance angiography and computed tomography angiography for the diagnosis and assessment of symptomatic, lower limb peripheral arterial disease. *Health Technol Assess*. 2007 May;11(20):iii-iv, xi-xiii, 1-184. Review.
22. Cordeiro MA, Lima JA. Atherosclerotic plaque characterization by multidetector row computed tomography angiography. *J Am Coll Cardiol*. 2006 Apr 18;47(8 Suppl):C40-7.
23. Easton JD, Saver JL, American Heart Association; American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Interdisciplinary Council on Peripheral Vascular Disease. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. *Stroke*. 2009 Jun;40(6):2276-93.
24. Einstein AJ, Henzlova MJ, Rajagopalan S. Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography. *JAMA*. 2007 Jul 18;298(3):317-23.
25. Fraioli F, Catalano C, Napoli A, Francone M, Venditti F, Danti M, et al. Low-dose multidetector-row CTA of the infra-renal aorta and lower extremity vessels: image quality and diagnostic accuracy in comparison with standard DSA. *Eur Radiol*. 2006 Jan;16(1):137-46.
26. Gerber TC, Carr JJ, Arai AE, Dixon RL, Ferrari VA, Gomes AS, et al. Ionizing radiation in cardiac imaging: a science advisory from the American Heart Association Committee on Cardiac Imaging of the Council on Clinical Cardiology and Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention. *Circulation*. 2009 Feb 24;119(7):1056-65.
27. Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Committee to Update the 1997 Exercise Testing Guidelines. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). *J Am Coll Cardiol*. 2002 Oct 16;40(8):1531-40. Erratum in: *J Am Coll Cardiol*. 2006 Oct 17;48(8):1731.
28. Gluecker TM, Mayr M, Schwarz J, Bilecen D, Voegelé T, Steiger J, et al. Comparison of CT angiography with MR angiography in the preoperative assessment of living kidney donors. *Transplantation*. 2008 Nov 15;86(9):1249-56.
29. Goldstein E, Savel RH, Ruggiero M, Shlasko E. Pulmonary sequestration: an aberrant systemic blood supply demonstrated by computed tomographic angiography with 3-dimensional reconstruction. *Ann Thorac Surg*. 2007 Oct;84(4):1402.
30. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster. AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *J Am Coll Cardiol*. 1999 Oct;34(4):1348-59
31. Ha HI, Seo JB, Lee SH, Kang JW, Goo HW, Lim TH, et al. Imaging of Marfan syndrome: multisystemic manifestations. *Radiographics*. 2007 Jul-Aug;27(4):989-1004.

32. Hausleiter J, Meyer T, Hadamitzky M, Zankl M, Gerein P, Dörrler K, et al. Non-invasive coronary computed tomographic angiography for patients with suspected coronary artery disease: the Coronary Angiography by Computed Tomography with the Use of a Submillimeter resolution (CACTUS) trial. *Eur Heart J*. 2007 Dec;28(24):3034-41.
33. Hausleiter J, Meyer T, Hermann F, Hadamitzky M, Krebs M, Gerber TC, et al. Estimated radiation dose associated with cardiac CT angiography. *JAMA*. 2009 Feb 4;301(5):500-7.
34. Hendel RC, et al. American College of Cardiology Foundation, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology 2006 Appropriateness Criteria for Cardiac Computed Tomography and Cardiac Magnetic Resonance Imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. *J Am Coll Cardiol*. 2006 Oct 3;48(7):1475-97.
35. Hendel RC, et al. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for cardiac radionuclide imaging: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine: endorsed by the American College of Emergency Physicians. *Circulation*. 2009 Jun 9;119(22):e561-87. Epub 2009 May 18.
36. Hirsch AT, Haskal ZJ, Hertzler NR, Bakal CW, Creager MA, Halperin JL, et al. American College of Cardiology Foundation and the American Heart Association, Inc. (ACC/AHA) 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter Society Consensus; and Vascular Disease Foundation. *J Am Coll Cardiol*. 2006 Mar 21;47(6):1239-312.
37. Hoffmann U, Bamberg F, Chae CU, Nichols JH, Rogers IS, Seneviratne SK, et al. Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial. *J Am Coll Cardiol*. 2009 May 5;53(18):1642-50.
38. Hogg K, Brown G, Dunning J, Wright J, Carley S, Foex B, Mackway-Jones K. Diagnosis of pulmonary embolism with CT pulmonary angiography: a systematic review. *Emerg Med J*. 2006 Mar;23(3):172-8.
39. Husmann L, Schepis T, Scheffel H, Gaemperli O, Leschka S, Valenta I, et al. Comparison of diagnostic accuracy of 64-slice computed tomography coronary angiography in patients with low, intermediate, and high cardiovascular risk. *Acad Radiol*. 2008 Apr;15(4):452-61.
40. Institute for Clinical Systems Improvement (ICSI). Venous Thromboembolism Diagnosis and Treatment Ninth Edition. February 2009. Accessed June 2009. Available at URL address: http://www.icsi.org/guidelines_and_more/gl_os_prot/cardiovascular/venous_thromboembolism/venous_thromboembolism_6.html
41. Johnston SC, Higashida RT, Barrow DL, Caplan LR, Dion JE, Committee on Cerebrovascular Imaging of the American Heart Association Council on Cardiovascular Radiology. Recommendations for the

endovascular treatment of intracranial aneurysms: a statement for healthcare professionals from the Committee on Cerebrovascular Imaging of the American Heart Association Council on Cardiovascular Radiology. *Stroke*. 2002 Oct;33(10):2536-44.

42. Josephs SC, Rowley HA, Rubin GD, American Heart Association Writing Group 3. Atherosclerotic Peripheral Vascular Disease Symposium II: vascular magnetic resonance and computed tomographic imaging. *Circulation*. 2008 Dec 16;118(25):2837-44.
43. Juraszek AL, Guleserian KJ. Common Aortic Arch Anomalies: Diagnosis and Management. *Curr Treat Options Cardiovasc Med*. 2006 Sep;8(5):414-418.
44. Kock MC, Adriaensen ME, Pattynama PM, van Sambeek MR, van Urk H, Stijnen T et al. DSA versus multi-detector row CTA in peripheral arterial disease: randomized controlled trial. *Radiology*. 2005 Nov;237(2):727-37.
45. Koelemay MJ, Nederkoorn PJ, Reitsma JB, Majoie CB. Systematic review of computed tomographic angiography for assessment of carotid artery disease. *Stroke*. 2004 Oct;35(10):2306-12.
46. Kokkinis C, Vlychou M, Zavras GM, Hadjigeorgiou GM, Papadimitriou A, Fezoulidis IV. The role of 3D-computed tomography angiography (3D-CTA) in investigation of spontaneous subarachnoid haemorrhage: comparison with digital subtraction angiography (DSA) and surgical findings. *Br J Neurosurg*. 2008 Feb;22(1):71-8.
47. Kramer CM, Budoff MJ, Fayad ZA, Ferrari VA, Goldman C, American College of Cardiology Foundation, American Heart Association, American College of Physicians Task Force on Clinical Competence and Training, et al. ACCF/AHA 2007 clinical competence statement on vascular imaging with computed tomography and magnetic resonance. A report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. *J Am Coll Cardiol*. 2007 Sep 11;50(11):1097-114.
48. Magnetic Resonance Angiography in Relatives of Patients with Subarachnoid Hemorrhage Study Group (The). Risks and benefits of screening for intracranial aneurysms in first-degree relatives of patients with sporadic subarachnoid hemorrhage. *N Engl J Med*. 1999;341:1344 –1350.
49. Masdeu JC, Irimia P, Asenbaum S, Bogousslavsky J, EFNS, et al. EFNS guideline on neuroimaging in acute stroke. Report of an EFNS task force. *Eur J Neurol*. 2006 Dec;13(12):1271-83.
50. Meijboom WB, Meijs MF, Schuijf JD, Cramer MJ, Mollet NR, van Mieghem CA, et al. Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. *J Am Coll Cardiol*. 2008 Dec 16;52(25):2135-44.
51. Meijboom WB, Mollet NR, Van Mieghem CA, Kluin J, Weustink AC, Pugliese F, et al. Pre-operative computed tomography coronary angiography to detect significant coronary artery disease in patients referred for cardiac valve surgery. *J Am Coll Cardiol*. 2006 Oct 17;48(8):1658-65.
52. Meijboom WB, van Mieghem CA, Mollet NR, Pugliese F, Weustink AC, van Pelt N, et al. 64-slice computed tomography coronary angiography in patients with high, intermediate, or low pre-test probability of significant coronary artery disease. *J Am Coll Cardiol*. 2007 Oct 9;50(15):1469-75.
53. Met R, Bipat S, Legemate DA, Reekers JA, Koelemay MJ. Diagnostic performance of computed tomography angiography in peripheral arterial disease: a systematic review and meta-analysis. *JAMA*. 2009 Jan 28;301(4):415-24.
54. Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Niinuma H, Gottlieb I, et al. Diagnostic performance of coronary angiography by 64-row CT. *N Engl J Med*. 2008 Nov 27;359(22):2324-36.

55. Mowatt G, Cook JA, Hillis GS, Walker S, Fraser C, Jia X, et al. 64-slice computed tomography angiography in the diagnosis and assessment of coronary artery disease: systematic review and meta-analysis. *Heart*. 2008a Jul 31. [Epub ahead of print]
56. Mowatt G, Cummins E, Waugh N, Walker S, Cook J, Jia X, et al. Systematic review of the clinical effectiveness and cost-effectiveness of 64-slice or higher computed tomography angiography as an alternative to invasive coronary angiography in the investigation of coronary artery disease. *Health Technol Assess*. 2008b May;12(17):1-164.
57. Nieman K, Cury RC, Ferencik M, Nomura CH, Abbara S, Hoffmann U, et al. Differentiation of recent and chronic myocardial infarction by cardiac computed tomography. *Am J Cardiol*. 2006 Aug 1;98(3):303-8.
58. Ouwendijk R, de Vries M, Stijnen T, Pattynama PM, van Sambeek MR, Program for the Assessment of Radiological Technology, et al. Multicenter randomized controlled trial of the costs and effects of noninvasive diagnostic imaging in patients with peripheral arterial disease: the DIPAD trial. *AJR Am J Roentgenol*. 2008 May;190(5):1349-57.
59. Ouwendijk R, de Vries M, Pattynama PM, van Sambeek MR, de Haan MW, Stijnen T et al. Imaging peripheral arterial disease: a randomized controlled trial comparing contrast-enhanced MR angiography and multi-detector row CTA. *Radiology*. 2005 Sep;236(3):1094-103.
60. Patel MR, Hurwitz LM, Orlando L, McCrory DC, Medicare Coverage Advisory Commission, et al. Noninvasive imaging for coronary artery disease: a technology assessment for the Medicare Coverage Advisory Commission. *Am Heart J*. 2007 Feb;153(2):161-74.
61. Radan L, Mor M, Gips S, Schlag-Eisenberg D, Lurie Y, Dickstein K, et al. The added value of spiral computed tomographic angiography after lung scintigraphy for the diagnosis of pulmonary embolism. *Clin Nucl Med*. 2004 Apr;29(4):255-61.
62. Reinartz P, Wildberger JE, Schaefer W, Nowak B, Mahnken AH, Buell U. Tomographic imaging in the diagnosis of pulmonary embolism: a comparison between V/Q lung scintigraphy in SPECT technique and multislice spiral CT. *J Nucl Med*. 2004 Sep;45(9):1501-8.
63. Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, et al. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. *J Am Coll Cardiol*. 1999 May;33(6):1756-824.
64. Schlosser T, Mohrs OK, Magedanz A, Nowak B, Voigtlander T, Barkhausen J, et al. Noninvasive coronary angiography using 64-detector-row computed tomography in patients with a low to moderate pre-test probability of significant coronary artery disease. *Acta Radiol*. 2007 Apr;48(3):300-7.
65. Schramm P, Schellinger PD, Klotz E, Kallenberg K, Fiebich JB, Kulkens S, et al. Comparison of perfusion computed tomography and computed tomography angiography source images with perfusion-weighted imaging and diffusion-weighted imaging in patients with acute stroke of less than 6 hours' duration. *Stroke*. 2004;35(7):1652-1658.
66. Schroeder S, Achenbach S, Bengel F, Burgstahler C, Working Group Nuclear Cardiology and Cardiac CT, European Society of Cardiology, European Council of Nuclear Cardiology, et al. Cardiac computed tomography: indications, applications, limitations, and training requirements: report of a Writing Group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuclear Cardiology. *Eur Heart J*. 2008 Feb;29(4):531-56. Epub 2007 Dec 15.
67. Stein PD, Fowler SE, Goodman LR, Gottschalk A, Hales CA, PIOPED II Investigators, et al. Multidetector computed tomography for acute pulmonary embolism. *N Engl J Med*. 2006 Jun 1;354(22):2317-27.

68. Stillman AE, Oudkerk M, Ackerman M, Becker CR, Buszman PE, de Feyter PJ, et al. Use of multidetector computed tomography for the assessment of acute chest pain: a consensus statement of the North American Society of Cardiac Imaging and the European Society of Cardiac Radiology. *Eur Radiol.* 2007 Aug;17(8):2196-207. Epub 2007 Jun 5.
69. Suarez JI, Tarr RW, Selman WR. Aneurysmal subarachnoid hemorrhage. *N Engl J Med.* 2006 Jan 26;354(4):387-96.
70. Sun Z, Jiang W. Diagnostic value of multislice computed tomography angiography in coronary artery disease: A meta-analysis. *Eur J Radiol.* 2006 Nov;60(2):279-86.
71. Vega C, Kwoon JV, Lavine SD. Intracranial aneurysms: current evidence and clinical practice. *Am Fam Physician.* 2002 Aug 15;66(4):601-8.
72. Warnes CA, Williams RG, American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease); American Society of Echocardiography; Heart Rhythm Society; International Society for Adult Congenital Heart Disease; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol.* 2008 Dec 2;52(23):e1-121.
73. Wermer MJ, Greebe P, Algra A, Rinkel GJ. Incidence of recurrent subarachnoid hemorrhage after clipping for ruptured intracranial aneurysms. *Stroke.* 2005a Nov;36(11):2394-9.
74. Wermer MJ, Koffijberg H, van der Schaaf IC; ASTRA Study Group. Effectiveness and costs of screening for aneurysms every 5 years after subarachnoid hemorrhage. *Neurology.* 2008 May 27;70(22):2053-62. Epub 2008 Apr 16.
75. Wermer MJ, van der Schaaf IC, Velthuis BK, Algra A, Buskens E, ASTRA Study Group, et al. Follow-up screening after subarachnoid haemorrhage: frequency and determinants of new aneurysms and enlargement of existing aneurysms. *Brain.* 2005b Oct;128(Pt 10):2421-9.
76. Willmann JK, Baumert B, Schertler T, Wildermuth S, Pfammatter T, Verdun FR et al. Aortoiliac and lower extremity arteries assessed with 16-detector row CTA: prospective comparison with digital subtraction angiography. *Radiology.* 2005 Sep;236(3):1083-93.
77. Woo D, Khoury J, Haverbusch MM, Sekar P, Flaherty ML, Kleindorfer DO, et al. Smoking and family history and risk of aneurysmal subarachnoid hemorrhage. *Neurology.* 2009 Jan 6;72(1):69-72.

APPENDIX A

From the American College of Cardiology (Hendel, et al., 2009):

Pre-Test Probability of CAD by Age, Gender, and Symptoms*

Age (Yrs)	Gender	Typical/Definite Angina Pectoris	Atypical/Probable Angina Pectoris	Nonanginal Chest Pain	Asymptomatic
<39	M	Intermediate	Intermediate	Low	Very low
	F	Intermediate	Very low	Very low	Very low

40-49	M F	High Intermediate	Intermediate Low	Intermediate Very low	Low Very low
50-59	M F	High Intermediate	Intermediate Intermediate	Intermediate Low	Low Very low
>60	M F	High High	Intermediate Intermediate	Intermediate Intermediate	Low Low

High: Greater than 90% pre-test probability; Intermediate: Between 10% and 90% pre-test probability;
Low: Between 5% and 10% pre-test probability; Very Low: Less than 5% pre-test probability.

*Modified from the ACC/AHA Exercise Testing Guidelines to reflect all age ranges (Gibbons, et al., 2002).

APPENDIX B

American College of Cardiology/American Heart Association (ACC/AHA) Definitions of Classification used:

- Class I: Conditions for which there is evidence for and/or general agreement that the procedure or treatment is beneficial, useful, and effective.
- Class II: Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/ efficacy of a procedure or treatment.
- Class IIa: Weight of evidence/opinion is in favor of usefulness/efficacy.
- Class IIb: Usefulness/efficacy is less well established by evidence/opinion.
- Class III: Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful/effective and in some cases may be harmful.

Policy History

Pre-Merger Organizations	Last Review Date	Policy Number	Title
CIGNA HealthCare	9/15/2008	0399	Computed Tomography Angiography (CTA)
Great-West Healthcare	11/27/2007	05.330.03	Computed Tomography Angiography (CTA) of Coronary Arteries, Contrast-Enhanced

"CIGNA" and the "Tree of Life" logo are registered service marks of CIGNA Intellectual Property, Inc., licensed for use by CIGNA Corporation and its operating subsidiaries. All products and services are provided exclusively by such operating subsidiaries and not by CIGNA Corporation. Such operating subsidiaries include Connecticut General Life Insurance Company, CIGNA Behavioral Health, Inc., Intracorp, and HMO or service company subsidiaries of CIGNA Health Corporation and CIGNA Dental Health, Inc. In Arizona, HMO plans are offered by CIGNA HealthCare of Arizona, Inc. In California, HMO plans are offered by CIGNA HealthCare of California, Inc. and Great-West Healthcare of California, Inc. In Connecticut, HMO plans are offered by CIGNA HealthCare of Connecticut, Inc. In North Carolina, HMO plans are offered by CIGNA HealthCare of North Carolina, Inc. In Virginia, HMO plans are offered by CIGNA HealthCare Mid-Atlantic, Inc. All other medical plans in these states are insured or administered by Connecticut General Life Insurance Company.

Connecticut General Life Insurance Company has acquired the business of Great-West Healthcare from Great-West Life & Annuity Insurance Company (GWLA). Certain products continue to be provided by GWLA (Life, Accident and Disability, and Excess Loss). GWLA is not licensed to do business in New York. In New York, these products are sold by GWLA's subsidiary, First Great-West Life & Annuity Insurance Company, White Plains, N.Y.